Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 3, 2005 (Second Quarter of Fiscal Year 2005)
Business Overview: Illumina develops and markets tools for the large-scale analysis of genetic variation and function, including oligonucleotides, genotyping systems (BeadLab, BeadStation), and gene expression systems. The company operates in the life sciences and pharmaceutical sectors.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 3, 2005 |
Six Months Ended July 3, 2005 |
Six Months Ended June 27, 2004 |
|---|---|---|---|
| Total Revenue | $15,824 | $30,972 | $22,289 |
| Net Loss | $(18,539) | $(19,774) | $(7,447) |
| Net Loss Per Share (Basic & Diluted) | $(0.46) | $(0.50) | $(0.22) |
| Cash and Cash Equivalents | $54,566 (as of July 3, 2005) | ||
| Operating Cash Flow | $(7,194) used (Six Months 2005) | ||
| Product Gross Margin | 68% (Six Months 2005) | ||
| Service Gross Margin | 75% (Six Months 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38% year-over-year for the six-month period ($30.97M vs. $22.29M). Product revenue grew 38% and service revenue grew 85%, driven by higher sales of BeadStation systems, consumables, and third-party SNP genotyping contracts.
- Significant One-Time Charge: The company recorded a non-cash charge of $15.8 million for acquired in-process research and development (IPR&D) related to the acquisition of CyVera Corporation. This charge was the primary driver of the increased net loss.
- Operating Expenses: Research and Development (R&D) expenses increased 26% year-over-year ($13.2M vs. $10.5M) due to higher overhead absorption and integration of CyVera technology. Selling, General, and Administrative (SG&A) expenses increased 6% ($12.5M vs. $11.7M), primarily due to sales force expansion, partially offset by reduced litigation costs.
- Litigation Resolution: A $5.9 million liability related to a termination-of-employment lawsuit was paid in January 2005, removing the liability from the balance sheet. No litigation judgment expense was recorded in the current period compared to $378,000 in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition of CyVera: Completed on April 8, 2005, for a total purchase price of $17.8 million. The acquisition aims to integrate digital microbead technology into Illumina's portfolio. First products based on this technology are expected in the second half of 2006.
- Liquidity Outlook: Management expects current cash, cash equivalents, and investments ($54.6 million) to fund operating needs for at least 24 months. No material capital expenditure commitments exist currently.
- Accounting Changes: The company expects to adopt SFAS 123R (Share-Based Payment) on January 2, 2006. This will result in significant non-cash charges to operating expenses but will not impact cash flows.
- Legal Risks:
- Affymetrix Litigation: Affymetrix alleges patent infringement regarding BeadArray products. Trial is scheduled for October 2006. An unfavorable outcome could materially adversely affect the business.
- Dr. Czarnik Lawsuit: A former employee filed a new suit in June 2005 alleging fraudulent omission of his name from patent applications, seeking damages and patent invalidation.
- Revenue Fluctuations: Revenue is subject to volatility due to the timing of high-value product sales and the completion of the International HapMap Project grant (which contributed 8% of revenue in the first six months of 2005 but is now largely complete).
Investor Verification Checklist
- CyVera Integration: Verify the timeline and commercial viability of the CyVera digital microbead technology, as $15.8 million of the purchase price was expensed immediately.
- Patent Litigation Status: Monitor the progress of the Affymetrix lawsuit and the new Dr. Czarnik inventorship claim, as adverse rulings could block product sales or invalidate core patents.
- Revenue Sustainability: Assess whether growth in third-party SNP genotyping services and new product launches (whole-genome arrays) will successfully offset the decline in HapMap grant-funded revenue.
- Stock-Based Compensation Impact: Review the projected impact of SFAS 123R adoption in 2006 on future reported earnings.
- Cash Burn Rate: Confirm that the $54.6 million cash balance remains sufficient to fund operations through the 24-month horizon given continued R&D and SG&A expansion.